Does Nashville Campus Expansion Change The Bull Case For Covista Stock (CVSA)?

• Covista, through its Chamberlain University unit, has already announced a new Nashville, Tennessee campus offering flexible nursing degree schedules. Applications open September 9, 2026, and classes begin January 4, 2027.
• The move expands Covista’s physical footprint into Tennessee and targets local nurse training capacity, directly aligning its operations with ongoing U.S. healthcare workforce shortages.
• Now we will see how this new Chamberlain campus expansion in Nashville could reshape Covista's broader investment narrative for investors.

Scan beyond Covista and the Nashville expansion news by sizing up hand-picked healthcare education and training peers using our 17 high quality undiscovered gems.

Covista Investment Narrative Recap

For a shareholder in Covista, the basic belief is that healthcare workforce shortages keep supporting demand for its training programs while the group executes on capacity expansion and digital learning. The Nashville campus fits that story but is one incremental site among a broader build out. The more immediate swing factor still sits with enrollment and margin trends at Chamberlain and Walden over the next few intakes. If application strength turns into higher utilization, the current revenue base of about US$1.95b and net income of roughly US$267 million may support the existing earnings profile. If conversion stays soft, pressure persists.

The announcement that Covista leaders will present at the Jefferies Healthcare Services and Technology Conference on 14 September 2026 looks more relevant than it first appears. Conference appearances give management a platform to refresh the narrative around Chamberlain enrollment, online program scale at Walden and capital allocation, especially with US$728 million of repurchase capacity still flagged by analysts. Investors get another checkpoint on how the firm thinks about program affordability, regulatory shifts around lending and the pace of new campus openings. Execution commentary around the Nashville launch should plug directly into those existing catalysts and worries.

Even so, there is a less obvious pressure point in the Covista story that only becomes clear when you look at ...

Read the full Covista narrative to see the case behind these numbers.

Covista's narrative projects US$2.4b revenue and US$362.8 million earnings by 2029. This involves 7.4% yearly revenue growth and an earnings increase of about US$95 million from current earnings of roughly US$267.4 million.

Covista's forecasts point to a $159.50 fair value versus the $125.91 share price, indicating a 27% upside to its current price that could narrow quickly.

Exploring Other Perspectives

Some of the most optimistic analysts saw Covista as a margin expansion story, not just a capacity one. They expected profit margins to move from about 13.4% to 16.2% and earnings to reach roughly US$380.6 million on US$2.3b revenue by 2029. Those projections came before this Nashville news, so you may want to reassess how their bullish view could shift.

To see how your view on Covista compares with the broader market, check out the 2 other fair value estimates for Covista.

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Covista research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• See our latest analysis for Covista. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Covista's overall financial health at a glance.

Looking For More Investment Ideas Beyond Covista?

If the Covista story has you thinking about portfolio gaps, it can help to line it up against other opportunities using the Simply Wall St Screener. You can scan for very different types of businesses without needing to build your own filters from scratch.

• If you want potential mispricings with solid fundamentals, start by reviewing our 31 high quality undervalued stocks and see which companies the numbers say could be trading below their estimated worth.
• If capital preservation is a priority, consider using the 10 resilient stocks with low risk scores to focus on businesses with more resilient risk profiles based on Simply Wall St's scoring.
• If you care most about financial strength, use the list of solid balance sheet and fundamentals (24 results) as a shortlist of companies where balance sheet quality and core fundamentals are front and center.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com